Moderna: data on cancer vaccine
(CercleFinance.com) - Moderna yesterday announced that two abstracts on mRNA-4157/V940 (MSD), an investigational personalized mRNA cancer vaccine, have been accepted for presentation at the American Association of Cancer Research (AACR) 2023 Annual Meeting to be held April 14-19 in Orlando, Fla.
The mRNA-4157/V940 is being jointly developed by Moderna and Merck, known as MSD outside the US and Canada.
The first abstract relates to the combination of MSD with pembrolizumab, the second assesses the efficacy of this combination.
Copyright (c) 2023 CercleFinance.com. All rights reserved.